Cavtat-Dubrovnik, Croatia
More info
News & events
Operational start of PLATINE, a joint immuno-monitoring platform
June 15, 2009
Innate Pharma, Transgene, ImmunID, Inserm and the cancer hospital Centre Léon-Bérard announced the operational start of PLATINE, a joint immuno-monitoring platform.
Innate Pharma to hold its Annual General Meeting of Shareholders on June 23, 2009, in Marseilles, France
June 5, 2009
Innate Pharma will hold its Annual General Meeting of Shareholders (“AGM”) on June 23, 2009, at 11 am in its headquarters, 117 avenue de Luminy, F-13009 Marseilles.
Innate Pharma reports preliminary Phase I clinical data for IPH 2101 (a novel, anti-KIR monoclonal antibody activating NK cells) at the ASCO meeting
May 29, 2009
- IPH 2101 was very well tolerated at all tested doses; the pharmacodynamic endpoint was met
- First Phase II trial with IPH 2101 used as a single agent in multiple myeloma to begin in 2009
Available on line:
- Poster on Phase I trial in Multiple Myeloma (preliminary data)
- Poster on Phase I trial in Acute Myeloid Leukemia (preliminary data)
2008 Reference Document is available
May 6, 2009
Reference Document includes Annual Report.
The English version of the Reference Document is available. In order to download it, please click the thumbnail.
Innate Pharma announces its turnover for the first quarter of 2009 and updates on its cash situation
May 5, 2009
- 2.5 million euros in turnover in the first quarter ending March 31, 2009
- 35.4 million euros in cash and cash equivalent as at March 31, 2009 (excluding 4.4 million euros in research tax credit refunded in April 2009)
- A total of 10.4 million euros in research tax credit refund since January 1, 2009
Innate Pharma appoints Marcel Rozencweig, MD, as Senior Vice President, clinical and regulatory strategy
April 27, 2009
Innate Pharma announces today the strengthening of its management team with the appointment of Marcel Rozencweig, MD, as Senior Vice President in charge of clinical and regulatory strategy.